Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07109726 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
A Phase 1 study of Breast Cancer and Ovarian Cancer, sponsored by Terremoto Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 205
- Enrollment target
- 15
- Study locations
NCT07109726: Recruiting Phase 1 study of Breast Cancer and Ovarian Cancer, sponsored by Terremoto Biosciences.
NCT07109726 is a Phase 1 study of Breast Cancer and Ovarian Cancer that is actively recruiting participants, run by Terremoto Biosciences. The registered enrollment target is 205 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 15 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07109726, a Phase 1 study of Breast Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Terremoto Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 205 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.
Conditions Studied
Interventions
- DRUG TER-2013
- DRUG Fulvestrant injection
Study Locations (15)
Texas
- NEXT Oncology - Austin
- MD Anderson Cancer Center - Houston
- START Center for Cancer Research - San Antonio
Florida
- Florida Cancer Specialists - Lake Nona - Orlando
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Rochester - Rochester
Missouri
- Washington Univ. School of Medicine - St Louis
Nebraska
- Nebraska Cancer Specialists - Omaha
North Carolina
- Carolina BioOncology Institute - Huntersville
Ohio
- UH Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2025-09-23 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 1 |
What NCT07109726 shows while recruiting
NCT07109726 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower).
The record links to 8 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which TER-2013 is the first listed.
NCT07109726 lists 15 locations in 13 states (Texas, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT07109726 about?
NCT07109726 is a clinical study titled "A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations". This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.
What is the current status of trial NCT07109726?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 205 participants. The study started on 2025-09-23. Estimated completion is 2029-02-28.
What conditions does trial NCT07109726 study?
This clinical trial studies the following conditions: Breast Cancer, Ovarian Cancer, Solid Tumor, Endometrial Cancer, Cervical Cancer.
What interventions are being tested in trial NCT07109726?
The interventions under investigation include: TER-2013 (DRUG), Fulvestrant injection (DRUG).
Who is sponsoring clinical trial NCT07109726?
This trial is sponsored by Terremoto Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07109726 being conducted?
This trial has 15 study locations across Florida, Massachusetts, Minnesota, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07109726's enrollment target sits among peer trials
205 357th of 1224 higher than 867 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI